Skip to content

Mace Consult launched as a new and independent business on 5 March 2026, through a carve-out from Mace Group. Mace Consult and Mace Construct operate as two independent businesses. Information, references and materials on this website may represent operations prior to this separation. Go to Mace Construct here.

GlaxoSmithKline

Igniting innovation and transforming research

Delivering world-class research and healthcare facilities

View of a tall modern glass building which is the UK HQ for GSK

Key takeaways

120,000

sq m masterplan

£350m

expansion

30

month delivery period

  • Enhanced GSK’s global facilities and forged a long-term partnership, supporting their mission to help people do more, feel better, and live longer. 
  • Achieved £60 million in cost savings and delivered the project six months ahead of schedule through meticulous planning, setting new safety and innovation standards. 
  • Pioneered the use of digital communications and fully integrated IT systems on-site, operational 24/7, ensuring seamless project execution. 

Mace has been a trusted partner of GSK for over two decades, playing a pivotal role in transforming their global facilities. This enduring partnership supports GSK's mission to help people do more, feel better, and live longer.

One of the standout achievements was the delivery of the 1 million sq ft GSK House, completed 30 months ahead of schedule and saving an impressive £60 million. This feat was made possible through meticulous planning and innovative approaches, setting new standards for safety and efficiency. 

In Ulverston, Mace managed a £350 million, 120,000 sq m masterplan, further showcasing their expertise in delivering large-scale projects. The project team was the first to implement digital communications and fully integrated IT systems on-site, operational 24/7, ensuring seamless execution and real-time collaboration. This pioneering use of technology not only enhanced project management but also set a benchmark for future developments. 

Throughout these projects, Mace's commitment to excellence and innovation has been unwavering. By enhancing GSK's facilities, we contributed to the company's global operations, fostering an environment where cutting-edge research and healthcare can thrive. 

Together, Mace and GSK continue to push the boundaries of what's possible, driving forward advancements that make a real difference in people's lives. 

Mace Logo

Mace Consult and Mace Group are now two independent businesses.

In 2025, a majority investment in Mace Consult by Private Equity at Goldman Sachs Alternatives was announced through a demerger from Mace Group.

This completed on 5 March 2026, with Mace Consult and Mace Group (which includes Mace Construct) now independent businesses. To continue, please choose whether you want to explore Mace Consult or Mace Construct.